Article

Rheumatoid Arthritis Linked to Increased Heart Disease Risk

Those suffering from rheumatoid arthritis are at increased risk of dying from cardiovascular disease, a new study finds.

Those suffering from rheumatoid arthritis (RA) are at increased risk of dying from cardiovascular disease, a new study finds. The study, published online today in the journal Arthritis Research & Therapy, found that the increased risk of cardiovascular disease was due to disease-related inflammation as well as risk factors that affect the general population.

In the study, 442 RA patients in Sweden were followed for five years from the date of diagnosis. During this time, the progression of their disease was measured using chemical markers of inflammation and physical appearance. Treatment methods were monitored along with risk factors for heart disease including weight, cholesterol levels, blood pressure, diabetes, and smoking.

Analysis of the data found that a new cardiovascular event such as heart disease, stroke, or deep venous thrombosis was correlated with intensity of the arthritis and presence of diabetes, high blood pressure, and triglyceride level. Treatment with disease modifying antirheumatic drugs reduced the risk of developing cardiovascular disease, but use of COX-2 inhibitors increased risk.

SourceCardiovascular events in early rheumatoid arthritis (RA) are a result of inflammatory burden and traditional risk factors: a five year prospective study [Arthritis Research & Therapy]

Related Videos
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
© 2024 MJH Life Sciences

All rights reserved.